This important milestone reflects the company’s ongoing commitment to advancing glaucoma care and expanding access to vision-preserving treatment options for surgeons and patients globally.
“We are proud to reach this important milestone for New World Medical,” said Raymond Kong, Chief Commercial Officer. “MDR certification reflects the tremendous effort and collaboration across our organization and enables us to continue supporting glaucoma surgeons in Europe with innovative solutions for their patients.”
Looking ahead, New World Medical is working toward adding additional products in its portfolio to the MDR certification with priority on the Ahmed ClearPath® ST (ACP ST), which is currently approved in over 20 countries globally and has become a trusted treatment option for surgeons managing refractory glaucoma.